Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21769477 | 0.95 | MAPT (0.47) | MAPTNPSR1MAPK1CACNA1GHTT | |
| SCHEMBL21769479 | 0.93 | NPSR1 (0.46) | MAPTNPSR1MAPK1CACNA1GHRH3 | |
| SCHEMBL21769244 | 0.91 | NPSR1 (0.48) | MAPTNPSR1MAPK1CACNA1GHTT | |
| SCHEMBL21769400 | 0.91 | NPSR1 (0.45) | NPSR1CACNA1GHRH3HTTALDH1A1 | |
| SCHEMBL21769473 | 0.88 | NPSR1 (0.48) | MAPTNPSR1MAPK1CACNA1GHTT | |
| SCHEMBL21769233 | 0.86 | KDM4E (0.50) | NPSR1CACNA1GHTTALDH1A1USP2 | |
| SCHEMBL21769534 | 0.84 | NPSR1 (0.48) | MAPTNPSR1MAPK1HRH3HTT | |
| SCHEMBL21769243 | 0.83 | NPSR1 (0.49) | MAPTNPSR1MAPK1HTTALDH1A1 | |
| SCHEMBL21769529 | 0.82 | NPSR1 (0.40) | NPSR1ALDH1A1CYP2C9TSHRCYP2C19 | |
| SCHEMBL21769398 | 0.81 | KDM4E (0.46) | NPSR1CACNA1GHTTALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | MAPT 1188/4885NPSR1 615/4885MAPK1 1104/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | MAPT 1188/4885NPSR1 615/4885MAPK1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.